Effect of Anti-CD4 Antibody UB-421 on HIV-1 Rebound after Treatment Interruption

• Published in: The New England journal of medicine Vol. 380; no. 16; pp. 1535 - 1545
• Main Authors: Wang, Chang-Yi, Wong, Wing-Wai, Tsai, Hung-Chin, Chen, Yen-Hsu, Kuo, Be-Sheng, Lynn, Shugene, Blazkova, Jana, Clarridge, Katherine E, Su, Hsiao-Wen, Lin, Chia-Ying, Tseng, Fan-Chen, Lai, Annie, Yang, Fu-Hung, Lin, Chen-Han, Tseng, William, Lin, Hsiao-Yi, Finstad, Connie L, Wong-Staal, Flossie, Hanson, Carl V, Chun, Tae-Wook, Liao, Mei-June
• Format: Journal Article
• Language: English
• Published: United States Massachusetts Medical Society 18.04.2019
• Subjects: Adult; Anti-Retroviral Agents - therapeutic use; Antibodies, Monoclonal, Humanized - adverse effects; Antibodies, Monoclonal, Humanized - pharmacology; Antibodies, Monoclonal, Humanized - therapeutic use; Antigens; Antiretroviral drugs; Antiretroviral therapy; Antiviral activity; Antiviral drugs; Binding sites; Body weight; CD4 antigen; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; Cytotoxicity; Drug dosages; Drug resistance; Exanthema; Exanthema - chemically induced; HIV; HIV Infections - drug therapy; HIV-1 - isolation & purification; Human immunodeficiency virus; Humans; Immunoregulation; Intravenous administration; Lymphocytes; Lymphocytes T; Male; Middle Aged; Mutation; Pharmacokinetics; Ribonucleic acid; RNA; Statistical analysis; T-Lymphocytes, Regulatory; Viral Load; Viremia; Viremia - drug therapy; Taiwan
• ISSN: 0028-4793; 1533-4406
• DOI: 10.1056/NEJMoa1802264

The in vivo activity of a monoclonal antibody that targets the CD4 binding site on T cells and blocks HIV-1 binding was assessed. In this study of antiretroviral treatment interruption involving persons with HIV-1 infection, activity of UB-421 was shown.